NCT06065670View on ClinicalTrials.gov

Assessing Changes in Multi-parametric MRI in Patients With Acute Demyelinating Lesions Taking Clemastine Fumarate as a Myelin Repair Therapy

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

44

Participants

Timeline

Start Date

September 15, 2024

Primary Completion Date

October 30, 2026

Study Completion Date

October 30, 2026

Conditions
Demyelinating DiseasesDemyelination; Corpus CallosumMultiple Sclerosis Brain LesionMultiple Sclerosis Acute and ProgressiveClinically Isolated Syndrome, CNS Demyelinating
Interventions
DRUG

Clemastine Fumarate

12 or 8 mg Clemastine tablet. Clemastine fumarate was approved by the Food and Drug Administration (FDA) for the treatment of allergic rhinitis (seasonal allergies) in 1977 and was approved for over-the-counter marketing in 1992. Clemastine is not FDA approved as a remyelinating therapy

DRUG

Placebo

Matched sugar tablet

Trial Locations (1)

94107

Sandler Neurosciences Building, Neurological Clinical Research Unit, San Francisco

All Listed Sponsors
lead

University of California, San Francisco

OTHER